Congress extends drug-shortage loophole for compounding pharmacies
H.R. 7528 — GAP Supply Act · Filed by Buddy Carter (R-GA) · Introduced Feb 12, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends federal pharmacy law to allow outsourcing facilities (compounding pharmacies) to continue supplying drugs for up to 180 days after a drug enters shortage status, rather than stopping immediately. The stated goal is to help mitigate drug shortages by giving these facilities a grace period to wind down production and distribution.
Why we flagged it
The bill functionally extends regulatory flexibility for compounding pharmacies during drug shortages by creating a 180-day tail period. It is neither a pure deregulation nor a pure public-health measure—it is a targeted carve-out that trades immediate oversight for supply continuity.
What the text implies
- The 180-day tail period may incentivize compounding facilities to delay reporting when a drug shortage ends, extending their market access beyond the actual shortage window.
- Outsourcing facilities operating under 503B are exempt from certain FDA manufacturing standards that apply to licensed pharmaceutical manufacturers; this extension may allow them to supply drugs at scale without meeting those standards.
The full analysis lists 4 implications of this text.
Who stands to gain
compounding pharmacies and outsourcing facilities; pharmaceutical compounding service providers